Navigation Links
PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer
Date:3/30/2011

Jay Barth will lead all clinical development programs for ataluren, an investigational new drug for the treatment of nonsense mutation genetic disorders.  Ataluren is currently being investigated for use in Duchenne and Becker muscular dystrophy, cystic fibrosis, hemophilia and methylmalonic acidemia due to a nonsense mutation.  Dr. Barth received his undergraduate degree from Columbia University and his medical degree from the University of Pennsylvania School of Medicine.  He completed a residency in Pediatrics at the Columbia-Presbyterian Medical Center and a fellowship in Pediatric Gastroenterology, Liver disease and Nutrition at the New England Medical Center.  In his previous role at Merck, Dr. Barth served as Executive Director of Clinical Development and was responsible for global clinical development programs in respiratory, supportive oncology and gastroenterology.  

"We are excited to welcome Dr. Spiegel as a member of our senior management team.  Bob's extensive clinical development experience, especially his track record in leading discussions with regulatory authorities, will be invaluable as we move ataluren toward regulatory filings," stated Dr. Stuart Peltz, President and CEO of PTC Therapeutics.  "Jay has been a key contributor to the successful execution of our ataluren development plan since 2009 and the expansion of his role further supports advancement of our development efforts with ataluren."

About PTC Therapeutics, Inc.  

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes.  Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders,
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... (April 16, 2014) A team that includes scientists from ... Science Center at San Antonio, Johns Hopkins University and St. ... a common fungus to infect the body. , The fungal ... and oral thrush, and is the most common fungal pathogen ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
(Date:4/14/2014)... Ford Hospital reached a medical milestone April 3, performing ... way to access the heart. , Henry Ford is ... unique procedure called transcaval valve replacement, which accesses the ... Michigan resident Viola Waller, 80, underwent Henry Ford,s first ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2
... Lomb is one of the leading company which manufactures contact ... serious eye infections in some users. // After ... inspect Bausch & Lomb facilities. There was extensive microbiological testing ... analyze the culprit behind the eye infection. Bausch & Lomb ...
... the wonder enzyme in sepsis increases the bodys vulnerability ... confers strong resistance to sepsis. // ,This ... humans. ,"The results of the study make ... elimination of bacterial pathogens, and that a deficiency allows ...
... it has been categorized in A,B and C. A biological ... call for special actions by the pubic health system. // ... at Rockefeller University which suggests that a newly discovered protein ... areas in which anthrax spores have been released. ...
... to the hospitals in the twin cities,following symtoms of cough, ... flu infection. // ,With this , the total ... ministry has confrimed that no H5N1 strain has been detected ... culled ever since the outbreak. ,The suspected bird ...
... behind the aggressive head and neck cancer was unveiled by ... // It is a highly malignant form of cancer ... triple interaction between CD44, hyaluronan (HA), and LARG. CD44 is ... a variety of cellular functions. Hyaluronan (HA) is a complex ...
... the more evident after this pathbreaking study. Overeating and ... children accoding to the study. // ,This study ... trend of childhood obesity, which is perhaps a reminder to ... advertisments targeting children. ,Nearly 5,407 students from 90 public ...
Cached Medicine News:Health News:Sepsis risk increased due to the absence of one key enzyme 2Health News:A Detail Analysis of Head and Neck Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: